CELU (Celularity) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CELU Celularity Inc CELU
42 GF Score
Price $1.86
GF Value $2.42
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Celularity Short-term investments?

Short-term investments only applies to insurance companies.

CELU
42GF Score
Celularity Inc CELU
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celularity (CELU) Overvalued in 2026?

Based on GuruFocus' analysis, Celularity stock appears to be undervalued. The current stock price of $1.86 is trading 23.1% below its estimated GF Value™ of $2.42. GuruFocus considers Celularity to be Modestly Undervalued.

Key valuation signals for CELU:

  • Short-term investments:
  • GF Value™: $2.42 vs. price of $1.86 (23.1% below fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the CELU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celularity Business Description

Address 170 Park Avenue, Florham Park, NJ, USA, 07932
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
42GF Score

Get the complete analysis for CELU

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.86
Price
$2.42
GF Value